AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20848453 — intervention group
Group type: EXPERIMENTAL
Intervention: NI-0401 (0.05-10 mg daily for 5 days)
Number of subjects: 40
Study 20848453 — intervention group
Group type: EXPERIMENTAL
Intervention: NI-0401 (1 mg)
Number of subjects: 40
Study 20848453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17428106 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0
Study 17428106 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast with antihistamines (loratadine or cetirizine)
Number of subjects: 0
Study 15994144 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 298
Study 15994144 — intervention group
Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 298
Study 12475674 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg alprostadil
Number of subjects: 303
Study 12475674 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg alprostadil
Number of subjects: 303
Study 12475674 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg alprostadil
Number of subjects: 303
Study 12475674 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg alprostadil
Number of subjects: 303
Study 12475674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 9857783 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication noncompliance and substance abuse
Number of subjects: 331
Study 9857783 — intervention group
Group type: EXPERIMENTAL
Intervention: Problems with both alcohol and illicit drug abuse
Number of subjects: 331
Study 9857783 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving medication adherence in the context of integrated mental health and substance abuse treatment
Number of subjects: 331
Study 7542829 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean daily dose 8 mg)
Number of subjects: 98
Study 7542829 — intervention group
Group type: COMPARATOR
Intervention: Zuclopenthixol (mean daily dose 38 mg)
Number of subjects: 98
Study 7542829 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 98
Study 31564184 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy with 20 Gy in five fractions followed by four cycles of chemotherapy (FOLFOX regimen)
Number of subjects: 29
Study 31656287 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (PAL)
Number of subjects: 70
Study 31656287 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (GRA)
Number of subjects: 70
Study 29723460 — intervention group
Group type: EXPERIMENTAL
Intervention: Qilan Capsules + androgen‐deprivation therapy
Number of subjects: 246
Study 29723460 — intervention group
Group type: COMPARATOR
Intervention: Placebo + androgen‐deprivation therapy
Number of subjects: 246
Study 26165256 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked plates
Number of subjects: 60
Study 26165256 — intervention group
Group type: COMPARATOR
Intervention: Nonlocked plates
Number of subjects: 60
Study 22472905 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Teaching (PT) for pain management
Number of subjects: 205
Study 22472905 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation/Music (RM)
Number of subjects: 205
Study 22472905 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PT and RM
Number of subjects: 205
Study 22472905 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 205
Study 21610513 — intervention group
Group type: EXPERIMENTAL
Intervention: benidipine-ARB
Number of subjects: 3501
Study 21610513 — intervention group
Group type: EXPERIMENTAL
Intervention: benidipine-β-blocker
Number of subjects: 3501
Study 21610513 — intervention group
Group type: COMPARATOR
Intervention: benidipine-thiazide
Number of subjects: 3501
Study 21610513 — intervention group
Group type: EXPERIMENTAL
Intervention: benidipine and thiazide diuretic
Number of subjects: 3501
Study 21610513 — intervention group
Group type: EXPERIMENTAL
Intervention: benidipine and ARB
Number of subjects: 3501
Study 19306978 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest drainage
Number of subjects: 24
Study 19306978 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 24
Study 17972364 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous highly active antiretroviral therapy (HAART)
Number of subjects: 273
Study 17972364 — intervention group
Group type: COMPARATOR
Intervention: 5 STIs of 1, 1, 2, 2, and 3 months' duration, each followed by 3 months of therapy
Number of subjects: 273
Study 17972364 — intervention group
Group type: EXPERIMENTAL
Intervention: Unboosted protease inhibitor (PI)-based HAART
Number of subjects: 273
Study 17972364 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitor-based HAART
Number of subjects: 273
Study 15143085 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose HER‐2/neu ICD protein vaccine (25 microg)
Number of subjects: 29
Study 15143085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose HER‐2/neu ICD protein vaccine (150 microg)
Number of subjects: 29
Study 15143085 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose HER‐2/neu ICD protein vaccine (900 microg)
Number of subjects: 29
Study 15143085 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of HER‐2/neu ICD protein vaccine
Number of subjects: 29
Study 15143085 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after immunizations
Number of subjects: 29
Study 11801946 — intervention group
Group type: EXPERIMENTAL
Intervention: TCRF turbinate treatment (mean energy 415 +/- 37 J/turbinate; n = 17)
Number of subjects: 22
Study 11801946 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (n = 5)
Number of subjects: 22
Study 11801946 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded examiner assessment
Number of subjects: 22
Study 11801946 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported CPAP adherence
Number of subjects: 22
Study 9494309 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived control over pain and taking pain medication
Number of subjects: 137
Study 9494309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain severity
Number of subjects: 137
Study 9494309 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with pain relief
Number of subjects: 137
Study 7914123 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxodolol
Number of subjects: 28
Study 7914123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2461906 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl starch (HES) solution
Number of subjects: 10
Study 2461906 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) solution
Number of subjects: 10
Study 2461906 — intervention group
Group type: COMPARATOR
Intervention: 10% dextran solution
Number of subjects: 10
Study 162674 — intervention group
Group type: EXPERIMENTAL
Intervention: O-(beta-hydroxyethyl) rutoside (HR)
Number of subjects: 69
Study 162674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 30033775 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE Healthy Lifestyles intervention (includes educational workshop, informational magazine, goal setting, weekly self-monitoring, tailored feedback, prompts, team-based goals, coaching for directors)
Number of subjects: 0
Study 29625849 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 10 U/kg/leg
Number of subjects: 241
Study 29625849 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 15 U/kg/leg
Number of subjects: 241
Study 29625849 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (both doses)
Number of subjects: 241
Study 29625849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 27492676 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 355
Study 27492676 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessed Housing Programs
Number of subjects: 355
Study 27492676 — intervention group
Group type: COMPARATOR
Intervention: Did Not Access Housing Programs
Number of subjects: 355
Study 24824955 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane+remifentanil (S-R)
Number of subjects: 93
Study 24824955 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol+remifentanil (P-R)
Number of subjects: 93
Study 24824955 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane+fentanyl (S-F)
Number of subjects: 93
Study 22100691 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 86
Study 22100691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 21570422 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher worksite social support
Number of subjects: 2878
Study 18156278 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitek 2 automated identification and susceptibility testing device, combined with direct inoculation of blood cultures
Number of subjects: 1498
Study 18156278 — intervention group
Group type: COMPARATOR
Intervention: Control arm used Vitek 1 system inoculated from subcultures
Number of subjects: 1498
Study 16688464 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal pain symptoms in various body sites
Number of subjects: 495
Study 16688464 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck pain
Number of subjects: 495
Study 16688464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle or foot pain
Number of subjects: 495
Study 16688464 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent pain in axial, upper limb, and lower limb areas
Number of subjects: 495
Study 14603872 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise training (3 days a week for 10 weeks, 20 to 45 minutes)
Number of subjects: 19
Study 14603872 — intervention group
Group type: COMPARATOR
Intervention: Nontraining subjects with diabetes
Number of subjects: 19
Study 14603872 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (nontraining)
Number of subjects: 19
Study 11012500 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric 2% lidocaine 4 ml intrathecally
Number of subjects: 70
Study 11012500 — intervention group
Group type: COMPARATOR
Intervention: Isobaric 2% prilocaine 4 ml intrathecally
Number of subjects: 70
Study 9161258 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic anesthesia
Number of subjects: 30
Study 9161258 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 30
Study 1420734 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mmol KCl
Number of subjects: 6
Study 1420734 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mmol NaCl
Number of subjects: 6
Study 1420734 — intervention group
Group type: COMPARATOR
Intervention: No additional salts
Number of subjects: 6
Study 3973246 — intervention group
Group type: EXPERIMENTAL
Intervention: Child management training
Number of subjects: 20
Study 3973246 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined child management plus planned activities
Number of subjects: 20
Study 3973246 — intervention group
Group type: COMPARATOR
Intervention: Social validation group (nonproblem children)
Number of subjects: 20
Study 31103642 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 4 weeks (2q4)
Number of subjects: 872
Study 31103642 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 8 weeks after 5 monthly doses (2q8)
Number of subjects: 872
Study 31103642 — intervention group
Group type: COMPARATOR
Intervention: Laser treatment
Number of subjects: 872
Study 31103642 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI (both 2q4 and 2q8)
Number of subjects: 872
Study 29388899 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session version of psychiatric management augmented with the MOTR
Number of subjects: 60
Study 29388899 — intervention group
Group type: COMPARATOR
Intervention: 10-session version of psychiatric management
Number of subjects: 60
Study 26677853 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 % oxygen
Number of subjects: 102
Study 26677853 — intervention group
Group type: COMPARATOR
Intervention: 30 % oxygen
Number of subjects: 102
Study 25441947 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant acupuncture (HT4)
Number of subjects: 52
Study 25441947 — intervention group
Group type: COMPARATOR
Intervention: Control acupuncture (BL60)
Number of subjects: 52
Study 25441947 — intervention group
Group type: EXPERIMENTAL
Intervention: Local acupuncture (HT3)
Number of subjects: 52
Study 25441947 — intervention group
Group type: COMPARATOR
Intervention: Naïve control group
Number of subjects: 52
Study 23207848 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic irrigation
Number of subjects: 30
Study 23207848 — intervention group
Group type: COMPARATOR
Intervention: Vacuum irrigation
Number of subjects: 30
Study 19543863 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Resurfacing (HR)
Number of subjects: 48
Study 19543863 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-head Total Hip Arthroplasty (THA)
Number of subjects: 48
Study 19543863 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 48
Study 17288677 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 212
Study 17288677 — intervention group
Group type: COMPARATOR
Intervention: Sertraline 50-200 mg/day
Number of subjects: 212
Study 15539894 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate followed by calcipotriol 50 microg/g once daily
Number of subjects: 501
Study 15539894 — intervention group
Group type: COMPARATOR
Intervention: Tacalcitol 4 microg/g once daily
Number of subjects: 501
Study 11157302 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (1 mg IV)
Number of subjects: 14
Study 11157302 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mg IV)
Number of subjects: 14
Study 11157302 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label glucagon (1 mg IV)
Number of subjects: 14
Study 9691869 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb 400 mg kg‐1 i.v.
Number of subjects: 20
Study 9691869 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oncotically matched plasma protein substitute 4.5% i.v.)
Number of subjects: 20
Study 8283308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide containing diet (Impact)
Number of subjects: 0
Study 8283308 — intervention group
Group type: COMPARATOR
Intervention: Standard high protein enteral feeding (control)
Number of subjects: 0
Study 2659291 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 295
Study 30819846 — intervention group
Group type: EXPERIMENTAL
Intervention: Knotted Floss (KF) technique
Number of subjects: 30
Study 30819846 — intervention group
Group type: COMPARATOR
Intervention: Conventional Flossing (CF) technique
Number of subjects: 30
Study 30819846 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Preference
Number of subjects: 30
Study 29536598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led video-based educational intervention
Number of subjects: 99
Study 26709158 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin powder for inhalation (TIP)
Number of subjects: 0
Study 24588543 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 500
Study 24588543 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 500
Study 22884560 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (500 to 1,000 mg orally twice daily)
Number of subjects: 32
Study 21047592 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate specific antigen (PSA) testing
Number of subjects: 3000
Study 21047592 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 3000
Study 21047592 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring, radiotherapy, and radical prostatectomy treatments
Number of subjects: 3000
Study 17573044 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS
Number of subjects: 301
Study 16338192 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised homeopathic care for 12 weeks
Number of subjects: 169
Study 16338192 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control using self-selected, conventional health care
Number of subjects: 169
Study 11980329 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 2 g per day (Group 1, n = 10)
Number of subjects: 20
Study 11980329 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin with cefpirome 2 g x 2 (Group 2, n = 10)
Number of subjects: 20
Study 10077374 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg) once daily
Number of subjects: 81
Study 10077374 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg) once daily
Number of subjects: 81
Study 10077374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 7562574 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous cocaine doses (0, 8, 16, 32 or 48 mg/70 kg) administered 1 hr after daily methadone
Number of subjects: 16
Study 7562574 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated intravenous cocaine doses (0, 8 or 32 mg/70 kg) administered 4 times per session at 14‐min intervals
Number of subjects: 16
Study 7562574 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher methadone doses (> 60 mg)
Number of subjects: 16
Study 7562574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine administration in methadone-maintained individuals
Number of subjects: 16
Study 2286358 — intervention group
Group type: EXPERIMENTAL
Intervention: CY-VAMP
Number of subjects: 32
Study 2286358 — intervention group
Group type: EXPERIMENTAL
Intervention: VERCY-VAMP
Number of subjects: 32
Study 2286358 — intervention group
Group type: COMPARATOR
Intervention: VAMP alone
Number of subjects: 32
Study 7396155 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 0.5 mg/kg
Number of subjects: 100
Study 7396155 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose
Number of subjects: 100
Study 31221782 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab/lenalidomide/dexamethasone
Number of subjects: 0
Study 31221782 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab/bortezomib/dexamethasone
Number of subjects: 0
Study 31221782 — intervention group
Group type: COMPARATOR
Intervention: Control (lenalidomide/dexamethasone)
Number of subjects: 0
Study 31221782 — intervention group
Group type: COMPARATOR
Intervention: Control (bortezomib/dexamethasone)
Number of subjects: 0
Study 31033073 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-surgery (1 year)
Number of subjects: 135
Study 31033073 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-surgery (5 years)
Number of subjects: 135
Study 31033073 — intervention group
Group type: COMPARATOR
Intervention: No RTW vs. RTW
Number of subjects: 135
Study 31033073 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for impaired RTW
Number of subjects: 135
Study 29078780 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple polyphenol extract (100 mg epicatechin daily for 4 weeks)
Number of subjects: 60
Study 29078780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25749867 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC0109-0012 administered subcutaneously at various dose levels (0.01-3 mg/kg) as single dose, once weekly, or multiple doses every second week for up to 12 doses.
Number of subjects: 116
Study 24732962 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based writing therapy with therapeutic interaction, 14 sessions
Number of subjects: 34
Study 24732962 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 34
Study 21362672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive hand washing education
Number of subjects: 275
Study 19779265 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL)
Number of subjects: 34
Study 19779265 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic hemoclip placement (EHP)
Number of subjects: 34
Study 17149515 — intervention group
Group type: EXPERIMENTAL
Intervention: At-risk drinking
Number of subjects: 8599
Study 17149515 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk drinking
Number of subjects: 8599
Study 17149515 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence
Number of subjects: 8599
Study 17149515 — intervention group
Group type: COMPARATOR
Intervention: Tobacco use
Number of subjects: 8599
Study 17149515 — intervention group
Group type: COMPARATOR
Intervention: Illicit drug use
Number of subjects: 8599
Study 16253137 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonus system for hospital doctors
Number of subjects: 2303
Study 16253137 — intervention group
Group type: COMPARATOR
Intervention: Weaker incentive bonus system
Number of subjects: 2303
Study 16253137 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger incentive bonus system
Number of subjects: 2303
Study 11914255 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (25 microg)
Number of subjects: 0
Study 11914255 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 0
Study 9801901 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacryocystographic examination in leprosy patients
Number of subjects: 2
Study 9801901 — intervention group
Group type: COMPARATOR
Intervention: Dacryocystographic examination in non-leprosy patients
Number of subjects: 2
Study 8552014 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral breast pump
Number of subjects: 32
Study 8552014 — intervention group
Group type: COMPARATOR
Intervention: Single breast pump
Number of subjects: 32
Study 2239122 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 20
Study 6994924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile cardiopulmonary bypass
Number of subjects: 0
Study 6994924 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile cardiopulmonary bypass
Number of subjects: 0
Study 31759809 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU augmented with TCT (n=30)
Number of subjects: 52
Study 31759809 — intervention group
Group type: COMPARATOR
Intervention: TAU (n=22)
Number of subjects: 52